• news.cision.com/
  • Episurf/
  • Results from study with Episealer® Knee implant accepted for presentation at Australian and New Zealand orthopaedic congress

Results from study with Episealer® Knee implant accepted for presentation at Australian and New Zealand orthopaedic congress

Report this content

Episurf Medical (Nasdaq: EPIS B) today announces that the abstract “Episealer, a mini metal implant for chondral injuries in the knee. A prospective single surgeon case series”, has been accepted for a podium presentation at the combined Australian and New Zealand Knee Societies meeting, which will take place in Queenstown, New Zealand, on October 27 - 29, 2022. The presentation will be held by Prof. Karl Eriksson from Stockholm South Hospital and The Karolinska Institute, Stockholm, Sweden.

The abstract reports on the clinical outcome for patients having undergone treatment with Episurf Medical’s personalised knee implant Episealer® for treatment of isolated chondral and osteochondral defects in the knee, at Stockholm South Hospital.

“We are very interested in following the results from this prospective study performed at Stockholm South Hospital, with follow up of Episealer® patients. We are about to introduce the Episealer® product family in Australia and New Zealand, and we are happy to see the interest shown from the Australian and New Zealand Knee Societies”, says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Tags: